​

Funding Round

Series B - Sienna Biopharmaceuticals

Series B - Sienna Biopharmaceuticals

Investment Firm

Overview

Clinical development and commercialization of innovative aesthetics and medical dermatology products based on scientific breakthroughs

Announced Date

Apr 24, 2017

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Venvest Capital

Venvest Capital

No designation

Participant Investors

8

Investor Name
Participant InvestorDavid Pyott
Participant InvestorClough Capital Partners
Participant InvestorOmega Funds
Participant InvestorARCH Venture Partners
Participant InvestorFidelity

Round Details and Background

Sienna Biopharmaceuticals raised $40000000 on 2017-04-24 in Series B

Clinical development and commercialization of innovative aesthetics and medical dermatology products based on scientific breakthroughs

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 03, 2018
Post-IPO Equity - Sienna Biopharmaceuticals
-undefined
Apr 24, 2017
Series B - Sienna Biopharmaceuticals
8-40.0M
Jul 12, 2016
Series A - Sienna Biopharmaceuticals
3-12.0M
Apr 28, 2016
Series A - Sienna Biopharmaceuticals
4-34.0M

Recent Activity

There is no recent news or activity for this profile.